About the Company
plus therapeutics, inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and manufacture of treatments for cancer and other diseases. its lead product candidate is doceplus, a protein-stabilized pegylated liposomal formulation of docetaxel for the treatment of small cell lung cancer. the company is also involved in developing doxoplus, a generic pegylated liposomal encapsulated doxorubicin to treat breast and ovarian cancer, multiple myeloma, and kaposi's sarcoma. it has a license agreement with nanotx, corp. to develop and commercialize nanotx's glioblastoma treatment. the company was formerly known as cytori therapeutics, inc. and changed its name to plus therapeutics, inc. in july 2019. plus therapeutics, inc. was founded in 1996 and is headquartered in austin, texas.
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $PSTV News
Plus Therapeutics Inc PSTV
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...
Plus Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights
AUSTIN, Texas, March 05, 2024 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted ...
Plus Therapeutics Completes Dosing in Cohort 5 of ReSPECT-LM Phase 1 Trial of Rhenium (186Re) Obisbemeda in Leptomeningeal Metastases
AUSTIN, Texas, March 11, 2024 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted ...
Plus Therapeutics, Inc. (NASDAQ:PSTV) Q4 2023 Earnings Call Transcript
Q4 2023 Earnings Call March 5, 2024 Plus Therapeutics, Inc. beats earnings expectations. Reported EPS is $-0.7, expectations ...
Plus Therapeutics Inc.: Plus Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights
The webcast will be available on the Company's website for 90 days following the live call. Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company developing targeted radiotherapeutics for ...
Q4 2023 Plus Therapeutics Inc Earnings Call
Sean Lee; Analyst; H.C. Wainwright & Co., LLC Edward Woo; Analyst; Ascendiant Capital Markets ...
Plus Therapeutics Inc PSTV
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Allogene Therapeutics, Inc. (NASDAQ:ALLO) Q4 2023 Earnings Call Transcript
March 14, 2024 Allogene Therapeutics, Inc. isn't one of the 30 most popular stocks among hedge funds at the end of the third ...
Plus Therapeutics Inc.
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...
PSTV Plus Therapeutics, Inc.
The overall quant rating is not an average of the factor grades listed. Instead, it gives greater weight to the metrics with the strongest predictive value.
Loading the latest forecasts...